Show Summary Details
Page of

Current trials in renal cell carcinoma 

Current trials in renal cell carcinoma
Current trials in renal cell carcinoma

Paul Nathan

and Anup Vinayan

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy).

date: 23 November 2017

• The advent of clinically useful targeted therapies for renal cell carcinoma (RCC) has resulted in a large expansion in clinical trial activity • Current trials focus on identifying optimal sequences and combinations of new agents as well as determining whether the new agents are active in the adjuvant setting • An understanding of mechanisms of resistance to targeted agents would inform the optimal use of new agents • Given the large number of possible combinations and sequences of new therapies that need to be assessed, innovative approaches to clinical trial design need to be considered.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.